Skip to content
About
About Us
Team & Board
Generic Medicines
Our Members
Advocacy & Policy
Overview
Federal Advocacy
State Advocacy
Tariff & Trade
Biosimilars
GDUFA/BsUFA User Fees
IP & Patent Reform
Inflation Reduction Act
Medicaid Generics Penalty
PBM Reform
Resources
Resource Center
Generic & Biosimilar
Medicines Savings Report
Advocacy Priorities
Biosimilars
Commitment to Quality
Events
All Events
GRx+Biosims 2026
Access! 2027
About
About Us
Team & Board
Generic Medicines
Our Members
Advocacy & Policy
Overview
Federal Advocacy
State Advocacy
Tariff & Trade
Biosimilars
GDUFA/BsUFA User Fees
IP & Patent Reform
Inflation Reduction Act
Medicaid Generics Penalty
PBM Reform
Resources
Resource Center
Generic & Biosimilar
Medicines Savings Report
Advocacy Priorities
Biosimilars
Commitment to Quality
Events
All Events
GRx+Biosims 2026
Access! 2027
JOIN
SEARCH
Home
Press Releases
Biosimilars Council Press Releases
Press Releases
Press Releases
June 6, 2022
AAM
Giuseppe Randazzo Joins AAM as Vice President, Sciences and Regulatory Affairs
Press Releases
May 16, 2022
AAM
Association for Accessible Medicines Names Craig Burton as Senior Vice President, Policy & Strategic Alliances, and Executive Director of the Biosimilars Council
Press Releases
May 11, 2022
AAM
AAM Statement on House Energy and Commerce Health Subcommittee Markup of H.R. 7667 Reauthorizing Generic Drug and Biosimilar User Fee Amendments
Press Releases
April 26, 2022
AAM
HHS Finds Biosimilars Use Results in “Significant Spending Reduction” For Medicare and Its Beneficiaries
Press Releases
February 17, 2022
AAM
AAM Announces 2022 Board of Directors
Press Releases
February 15, 2022
AAM
Academy of Managed Care Pharmacy Named AAM’s 2022 Champion of Access
Press Releases
February 15, 2022
AAM
AAM Statement on the Confirmation of Robert Califf to Lead FDA
Press Releases
February 14, 2022
AAM
AAM Announces 2022 Associate Members
Press Releases
February 14, 2022
AAM
Chirag Patel Named Chair of the Association for Accessible Medicines Board of Directors
Press Releases
February 2, 2022
AAM
AAM Statement on FDA User Fee Reauthorization
Press Releases
February 1, 2022
AAM
Avalere Analysis Finds Medicare Part D Patients Continue to Pay More for Generics
Press Releases
January 20, 2022
AAM
New Study Shows Seniors Paid Nearly $22 Billion in Extra Out-of-Pocket Costs for Generic Medicines
Load More
Resources
2025 Savings Report
2025 Advocacy Priorities
2025 First Generics White Paper
Drug Shortages White Paper
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Blog
Founders Blogs
Amicus Briefs
Patient Stories
About the Association
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Community Commitment
Careers
Contact Us
Advocacy & Policy
Federal Advocacy
Biosimilars
GDUFA/BsUFA User Fees
Inflation Reduction Act
Intellectual Property & Patent Reform
Medicaid Generics Penalty
State Advocacy
Tariffs & Trade
Events
Access! 2026
GRx+Biosims 2026
Press Releases
JOIN
About
About Us
Team & Board
Generic Medicines
Our Members
Advocacy & Policy
Overview
Federal Advocacy
State Advocacy
Tariff & Trade
Biosimilars
GDUFA/BsUFA User Fees
IP & Patent Reform
Inflation Reduction Act
Medicaid Generics Penalty
PBM Reform
Resources
Resource Center
Generic & Biosimilar
Medicines Savings Report
Advocacy Priorities
Biosimilars
Commitment to Quality
Events
All Events
GRx+Biosims 2026
Access! 2027
JOIN
SEARCH